International Clinics
Daily
FDA approves talazoparib with enzalutamide for HRR-mutated hormone-sensitive metastatic prostate cancer
On 26 October 2026 the FDA approved Talzenna (talazoparib) with enzalutamide for metastatic prostate cancer.